Imagin Molecular Corporation is dedicated to business opportunities in the nuclear medicine field with its primary focus in positron emission tomography or as its most commonly known as PET. PET is the leading technology in the diagnosis of cancer, heart disease and neurological diseases. Imagin Molecular strategy is to build a portfolio of PET imaging centers for the prevention, management and reversal of coronary artery disease. Imagin Molecular’s imaging center model is unique to the industry and first to market the use of PET technology to guide the non-surgical reversal and prevention of coronary disease. Imagin Molecular plans to build, acquire and form joint ventures across North America in PET imaging centers business and continue to make investments in PET industry related opportunities.
